Regeneron Announced Sunday At ESMO, Updated Phase 3 C-POST Data Showing Libtayo Reduced Risk Of Death By 37% Vs. Placebo At 44-Month Follow-Up In High-Risk Cutaneous Squamous Cell Carcinoma

뉴스 본문을 불러오고 있어요.

Regeneron Announced Sunday At ESMO, Updated Phase 3 C-POST Data Showing Libtayo Reduced Risk Of Death By 37% Vs. Placebo At 44-Month Follow-Up In High-Risk Cutaneous Squamous Cell Carcinoma | 웨이프 WAPE

Regeneron Announced Sunday At ESMO, Updated Phase 3 C-POST Data Showing Libtayo Reduced Risk Of Death By 37% Vs. Placebo At 44-Month Follow-Up In High-Risk Cutaneous Squamous Cell Carcinoma

기사 요약

관련 종목

댓글 —